1268
LI ET AL.
ANTIMICROB. AGENTS CHEMOTHER.
FIG. 5. Time-kill curve of NB2001 and triclosan against -lactamase-producing E. coli. The compounds were added to log-phase cultures of
E. coli/TEM-1 and incubated at 37°C. Culture aliquots were removed every hour up to 6 h, and the number of cells (CFU) was determined as
described in Materials and Methods.
contributing factor to -lactam resistance. Antimicrob. Agents Chemother.
(24), such as cell wall synthesis, protein synthesis, or DNA
gyrase. ECTA represents a novel approach in that bacterium-
38:1742–1752.
14. Livermore, D. M. 1995. -Lactamases in laboratory and clinical resistance.
specific, enzymatic antibiotic activation allows the use of anti-
biotics with toxic liabilities, thus expanding the number of
bacterial targets. In addition, as the case of NB2001 clearly
shows, the ECTA approach is an effective way of harnessing
drug resistance caused by enzyme overexpression.
Clin. Microbiol. Rev. 8:557–584.
15. Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and
-lactamase induction. J. Antimicrob. Chemother. 24(Suppl. B):23–33.
16. Maranan, M. C., B. Moreira, S. Boyle-Vavra, and R. S. Daum. 1997. Anti-
microbial resistance in staphylococci. Epidemiology, molecular mechanisms,
and clinical relevance. Infect. Dis. Clin. North Am. 11:813–849.
17. Medeiros, A. A. 1984. -Lactamases. Br. Med. Bull. 40:18–27.
18. Medeiros, A. A. 1997. Evolution and dissemination of beta-lactamases ac-
celerated by generations of beta-lactam antibiotics. Clin. Infect. Dis.
24(Suppl. 1):S19–S45.
ACKNOWLEDGMENTS
We gratefully acknowledge Nafsika Georgopapadakou for helpful
discussions and valuable aid during the revision of the manuscript.
Thanks are also extended to Analia Bueno for technical contributions
in the evaluation of NB2001.
19. Muder, R. R., C. Brennen, M. M. Wagener, R. M. Vickers, J. D. Rihs, G. A.
Hancock, Y. C. Yee, J. M. Miller, and V. L. Yu. 1991. Methicillin-resistant
staphylococcal colonization and infection in a long-term care facility. Ann.
Intern. Med. 114:107–112.
20. Mulligan, M. E., K. A. Murray-Leisure, B. S. Ribner, H. C. Standiford, J. F.
John, J. A. Korvick, C. A. Kauffman, and V. L. Yu. 1993. Methicillin-resistant
Staphylococcus aureus: a consensus review of the microbiology, pathogenesis,
and epidemiology with implications for prevention and management. Am. J.
Med. 94:313–328.
21. Murray, B. E. 1997. Antibiotic resistance. Adv. Intern. Med. 42:339–367.
22. Musher, D. M. 2000. Streptococcus pneumoniae, p. 2130–2139. In G. L.
Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infec-
tious diseases, 5th ed., vol. 2. Churchill Livingstone, Philadelphia, Pa.
23. Nakae, T. 1997. Multiantibiotic resistance caused by active drug extrusion in
Pseudomonas aeruginosa and other gram-negative bacteria. Microbiologia
13:273–284.
24. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 257:1064–1073.
25. Nicolas-Chanoine, M. H. 1997. Inhibitor-resistant -lactamases. J. Antimi-
crob. Chemother. 40:1–3.
26. Opal, M. O., K. H. Mayer, and A. A. Medeiros. 2000. Mechanisms of bac-
terial antibiotic resistance, p. 236–253. In G. L. Mandell, J. E. Bennett, and
R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed., vol. 1.
Churchill Livingstone, Philadelphia, Pa.
27. Peacock, J. E., Jr., D. R. Moorman, R. P. Wenzel, and G. L. Mandell. 1981.
Methicillin-resistant Staphylococcus aureus: microbiologic characteristics,
antimicrobial susceptibilities, and assessment of virulence of an epidemic
strain. J. Infect. Dis. 144:575–582.
REFERENCES
1. Banerjee, S., U. Pieper, G. Kapadia, L. K. Pannell, and O. Herzberg. 1998.
Role of the omega-loop in the activity, substrate specificity, and structure of
class A -lactamase. Biochemistry 37:3286–3296.
2. Bhargava, H. N., and P. A. Leonard. 1996. Triclosan: applications and safety.
Am. J. Infect. Control. 24:209–218.
3. Bush, K. 2001. New -lactamases in gram-negative bacteria: diversity and im-
pact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085–1089.
4. Chen, H. Y., M. Yuan, and D. M. Livermore. 1995. Mechanisms of resistance
to -lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in
the UK in 1993. J. Med. Microbiol. 43:300–309.
5. Ferraro, M. J. 2000. Methods for dilution antimicrobial susceptibility test for
bacteria that grow aerobically, 5th ed. Approved standard. National Com-
mittee for Clinical Laboratory Standards, Wayne, Pa.
6. Haley, R. W., A. W. Hightower, R. F. Khabbaz, C. Thornsberry, W. J.
Martone, J. R. Allen, and J. M. Hughes. 1982. The emergence of methicillin-
resistant Staphylococcus aureus infections in United States hospitals. Possible
role of the house staff-patient transfer circuit. Ann. Intern. Med. 97:297–308.
7. Heath, R. J., J. R. Rubin, D. R. Holland, E. Zhang, M. E. Snow, and C. O.
Rock. 1999. Mechanism of triclosan inhibition of bacterial fatty acid synthesis
J. Biol. Chem. 274:11110–11114.
8. Heath, R. J., Y. T. Yu, M. A. Shapiro, E. Olson, and C. O. Rock. 1998. Broad
spectrum antimicrobial biocides target the FabI component of fatty acid
synthesis. J. Biol. Chem. 273:30316–30320.
9. Jones, R. N., and M. A. Pfaller. 1998. Bacterial resistance: a worldwide
problem. Diagn. Microbiol. Infect. Dis. 31:379–388.
28. Randall, J. L., and J. E. Godlewski. September 1998. Process for making
quinolonyl lactam antimicrobials and novel intermediate compounds. U.S.
patent 5,801,242.
29. Schaechter, M. 1993. Teaching microbiology to medical students. Infect.
Agents Dis. 2:394–397.
10. Kazmierczak, A., X. Cordin, J. M. Duez, E. Siebor, A. Pechinot, and J. Sirot.
1990. Differences between clavulanic acid and sulbactam in induction and inhi-
bition of cephalosporinases in enterobacteria. J. Int. Med. Res. 18:67D–77D.
11. Knox, J. R., P. C. Moews, and J. M. Frere. 1996. Molecular evolution of
bacterial -lactam resistance. Chem. Biol. 3:937–947.
12. Levy, C. W., A. Roujeinikova, S. Sedelnikova, P. J. Baker, A. R. Stuitje, A. R.
Slabas, D. W. Rice, and J. B. Rafferty. 1999. Molecular basis of triclosan
activity. Nature 398:383–384.
30. Steinberg, J. P., C. C. Clark, and B. O. Hackman. 1996. Nosocomial and
community-acquired Staphylococcus aureus bacteremias from 1980 to 1993:
impact of intravascular devices and methicillin resistance. Clin. Infect. Dis.
23:255–259.
31. Waldvogel, F. A. 2000. Staphylococcus aureus, p. 2069–2091. In G. L. Mandell,
J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases,
5th ed., vol. 2. Churchill Livingstone, Philadelphia, Pa.
32. Waxman, D. J., and J. L. Strominger. 1983. Penicillin-binding proteins and
the mechanism of action of -lactam antibiotics. Annu. Rev. Biochem. 52:
825–869.
13. Li, X. Z., D. Ma, D. M. Livermore, and H. Nikaido. 1994. Role of efflux
pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a